Search results for: 'antibody deals and alliances of 2016'

Provides a detailed understanding and analysis of how and why companies enter Big Pharma partnering deals

Regenerative Medicine Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Licensing Deals in Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2020 to 2026

Psychiatry Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2019 to 2025

Metabolic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2019 to 2025

Comprehensive Business Intelligence for Strategic Decision-Making

Drug Delivery Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

Academic and Non-Profit Partnering Terms and Agreements 2021-2026 provides a detailed understanding and analysis of how and why companies enter Academic and Non-Profit partnering deals. 

Genomics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2018 to 2025

Specialty Pharmaceutical Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals.